Conference Coverage 

FEATURED: Live Coverage from NANETs 2014

NANETS: Despite Dose Reductions, Everolimus Promising in Advanced Pancreatic Neuroendocrine Tumors

NANETS: Despite Dose Reductions, Everolimus Promising in Advanced Pancreatic Neuroendocrine Tumors

Everolimus is a promising treatment option for pancreatic neuroendocrine tumors (pNETs), even though dose reductions are required for most patients.

NANETS: Intraoperative 5-FU May Reduce Need for Additional Surgeries in Midgut Neuroendocrine Tumors

NANETS: Intraoperative 5-FU May Reduce Need for Additional Surgeries in Midgut Neuroendocrine Tumors

Intraoperatively-placed 5-fluouracil (5-FU) chemotherapy at lymph node surgical dissection beds may lower the chance of necessary surgery.

NANETS: Pancreatic Neuroendocrine Tumors Harbor DNA Repair Gene Defects

NANETS: Pancreatic Neuroendocrine Tumors Harbor DNA Repair Gene Defects

Pancreatic neuroendocrine tumors (pNETs) harbor genetic mutations in DNA repair pathways that represent "strong candidates".

Latest Conference News

HPV-Targeted Adoptive T-cell Therapy Induces Regression in Metastatic Cervical Cancer

HPV-Targeted Adoptive T-cell Therapy Induces Regression in Metastatic Cervical Cancer

CHICAGO, IL—Durable, complete tumor regression can occur following a single infusion of human papillomavirus tumor-infiltrating lymphocytes in women with metastatic cervical cancer.

Ibrutinib 'Effective New Single-agent Therapy' for Relapsed/Refractory CLL

Ibrutinib 'Effective New Single-agent Therapy' for Relapsed/Refractory CLL

CHICAGO, IL—Ibrutinib significantly improved progression-free survival, overall survival, and overall response rate when compared with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Biomarkers Fail to Predict Platinum Chemo Response in TNBC

Biomarkers Fail to Predict Platinum Chemo Response in TNBC

CHICAGO, IL—Established biomarkers failed to predict response to platinum in patients with metastatic triple-negative breast cancer.

Discontinuing Statins OK for Terminal Patients

Discontinuing Statins OK for Terminal Patients

CHICAGO, IL— Discontinuation of statin therapy does not shorten survival and improves quality of life among patients with a life expectancy of less than 1 year.

Afatinib + Paclitaxel Effective in EGFR Inhibitor-resistant Lung Cancer

Afatinib + Paclitaxel Effective in EGFR Inhibitor-resistant Lung Cancer

CHICAGO, IL— Non-small cell lung cancer tumors that progress on the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib/gefitinib and afatinib continue to depend on ErbB family receptor signaling.

Novel Kinase Inhibitor Shows Efficacy in Patients with Advanced HCC Tumors Overexpressing AFP

Novel Kinase Inhibitor Shows Efficacy in Patients with Advanced HCC Tumors Overexpressing AFP

LY2157299 monohydrate showed promising efficacy results in patients with advanced HCC tumors overexpressing AFP.

CTCs Have High Specificity for Diagnosis of Pancreatic Ductal Adenocarcinoma

CTCs Have High Specificity for Diagnosis of Pancreatic Ductal Adenocarcinoma

Circulating tumor cells are a useful adjunct in the diagnosis of pancreatic ductal adenocarcinoma.

PET/CT Can Prevent 'Futile Laparotomy' in Resectable/Borderline Pancreatic Cancer

PET/CT Can Prevent 'Futile Laparotomy' in Resectable/Borderline Pancreatic Cancer

PET/CT may prevent unnecessary laparotomy by detecting occult metastatic disease in patients with resectable/borderline pancreatic cancer.

Nab-Paclitaxel Plus Gemcitabine Sustains OS in Metastatic Pancreatic Adenocarcinoma

Nab-Paclitaxel Plus Gemcitabine Sustains OS in Metastatic Pancreatic Adenocarcinoma

Nab-paclitaxel plus gemcitabine sustained overall survival rates compared with gemcitabine alone in patients with metastatic pancreatic adenocarcinoma.

Cetuximab Does Not Improve FOLFOX4 Outcomes for CRC with RAS Mutations

Cetuximab Does Not Improve FOLFOX4 Outcomes for CRC with RAS Mutations

Cetuximab should not be added to first-line FOLFOX4 for patients whose mCRC harbors RAS mutations.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs